A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

Journal of the American Academy of Dermatology

Volumn 47, Issue 6, 2002, Pages 821-833

  Krueger, Gerald G ^a,g   Papp, Kim A ^b   Stough, Dow B ^c   Loven, Keith H ^d   Gulliver, Wayne P ^e   Ellis, Charles N ^f  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b PROBITY MEDICAL RESEARCH   (Canada)

^c Stough Clinic   (United States)

^d Rivergate Dermatol/Skin Care Ctr   (United States)

^e Newlab Clinical Research Inc   (Canada)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; PLACEBO;

ACCIDENT; ADOLESCENT; ADULT; AGED; ARTICLE; CHILL; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EVALUATION; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; INCIDENCE; INFECTION; INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SYSTEMIC THERAPY; TREATMENT OUTCOME;

EID: 0036895587     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.127247     Document Type: Article

References (37)

1. Christophers E. Psoriasis - Epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-20.
2. Barker JN. Psoriasis as a T cell-mediated autoimmune disease. Hosp Med 1998;59:530-3.
3. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999;113:752-9.
4. Bos JD, De Rie MA. The pathogenesis of psoriasis: Immunological facts and speculations. Immunol Today 1999;20:40-6.
5. Friedrich M, Krammig S, Henze M, Docke WD, Sterry W, Asadullah K. Flow cytometric characterization of lesional T cells in psoriasis: Intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res 2000;292:519-21.
6. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7.
7. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-4.
8. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999;41:51-9.
9. Bos JD, Meinardi MM, van Joost T, Heule F, Powles AV, Fry L. Use of cyclosporin in psoriasis. Lancet 1989;30:1500-2.
10. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, et al. Cyclosporine for plaque-type psoriasis: Results of a multidose, double-blind trial. N Engl J Med 1991;324:277-84.
11. van Dooren-Greebe RJ, Kuijpers AL, Mulder J, De Boo T, van de Kerkhof PC. Methotrexate revisited: Effects of long-term treatment in psoriasis. Br J Dermatol 1994;130:204-10.
12. Alarcón GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, et al, for the Methotrexate-Lung Study Group. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Ann Intern Med 1997;127:356-64.
13. Methotrexate (Lederle Pharmaceutical, Pearl River, NY) prescribing information. 2002.
14. Stern RS, Liebman EJ, Väkevä L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. J Natl Cancer Inst 1998;90:1278-84.
15. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001;44:755-61.
16. Lindelöf B. Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits? Drug Safety 1999;20:289-97.
17. Gordon KB, West DP. Biologic therapy in dermatology. In: Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy. Philadelphia: Saunders; 2001. p. 928-42.
18. Ontak™ (Denileukin Diftitox), Ligand Pharmaceuticals Incorporated, San Diego, Calif, prescribing information. 2002.
19. 389IL-2) in patients with severe psoriasis. J Am Acad Dermatol 2001;45:871-81.
20. Anonymous. Investigational strategies for biologic therapy of psoriasis. Skin Allergy News 2001;32(Suppl 2): 6, 9.
21. Papp K, Bissonnette R, Krueger JG, Carey W, Gratton D, Gulliver WP, et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001;45:665-74.
22. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
23. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Invest Dermatol 1999;103:1243-52.
24. Gottlieb AB, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000;42:428-35.
25. Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD, et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993;178:211-22.
26. 1 fusion protein on nonhuman primates. Ther Immunol 1994;1:205-16.
27. 1 fusion protein: Cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Ther Immunol 1995;2:159-71.
28. Sanders ME, Makgoba MW, Sharrow SO, Stephany D, Springer TA, Young HA, et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production. J Immunol 1988;140:1401-7.
29. + T cells is independent of cell activation. Cell Adhes Commun 1999;7:267-79.
30. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses: Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 1994;152:2753-67.
31. Ellis CN, Krueger GG, for the Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-SS.
32. Gottlieb A, Casale T, Goffe B, Gordon K, Korman N, Lowe N, et al. Impact of a 12-week course of alefacept therapy on primary and secondary immune responses in psoriasis patients [abstract]. J Eur Acad Dermatol Venereol 2001;1S(Suppl 2):242. Abstract P24-21.
33. Ellis C, Krueger G, Shrager D. Repeated courses of alefacept therapy in chronic plaque psoriasis provide consistent efficacy and safety [abstract]. J Eur Acad Dermatol Venereol 2001;15(Suppl 2):246. Abstract P24-38.
34. Fredriksson T, Pettersson U. Severe psoriasis coral therapy with a new retinoid. Dermatologica 1978;157:238-44.
35. Al-Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000;42:796-802.
36. van Dooren-Greebe RJ, Kuijpers AL, Termorshuizen F, van de Kerkhof PC. Interruption of long-term methotrexate treatment in psoriasis. Acta Derm Venereol 1995;75:393-6.
37. Giannotti B, Carli P, Varotti C, Neri I. Treatment of psoriasis with calcipotriol: Time of onset and healing of relapses. Eur J Dermaol 1997;7:275-8.